Mauricio Velez, MD
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1780629253
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Abbott at 34.1% of the total. Reporting peaked in 2019 at $1,578 and has fallen 59.7% since, to $635 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in FL, where the typical reported total is $7,029.
Across 166 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$2K
- Novartis$846
- Biosense Webster, Inc.$383
- Medtronic$275
- Edwards Lifesciences$262
- plus $870 from 12 others
Across 7 payments — averaging $4649.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$22K
- Endotronix, Inc.$11K
What the payments were for
- Travel & lodging$3536%
- Food & beverage$5,98593%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 59 | $2,181 |
| Abiomed | 14 | $1,585 |
| Novartis | 56 | $846 |
| Biosense Webster, Inc. | 10 | $383 |
| Medtronic(2 entities) | 3 | $275 |
| Edwards Lifesciences | 2 | $262 |
| Boston Scientific | 5 | $206 |
| Impulse Dynamics (USA) Inc. | 2 | $171 |
| Cardiva Medical, Inc. | 2 | $115 |
| Biotronik Inc. | 1 | $108 |
| Bridgebio Pharma, Inc. | 2 | $62 |
| Johnson & Johnson | 3 | $55 |
| Pfizer | 2 | $38 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,404 in reported general payments places this provider in the 45th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 238 | $300,611 |
| JardianceEmpagliflozin | 134 | $155,394 |
| FarxigaDapagliflozin Propanediol | 113 | $140,551 |
| EliquisApixaban | 65 | $95,084 |
| XareltoRivaroxaban | 17 | $24,960 |
| Tacrolimus | 24 | $8,784 |
| Torsemide | 144 | $4,985 |
| Metoprolol Succinate | 175 | $2,474 |
| Carvedilol | 157 | $1,879 |
| Isosorbide Dinitrate | 22 | $1,769 |
| Eplerenone | 30 | $1,759 |
| Potassium Chloride | 48 | $1,516 |
| Rosuvastatin Calcium | 73 | $1,375 |
| Spironolactone | 120 | $893 |
| Bumetanide | 22 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $846 | $300,611238 claims |
| AstraZenecaFarxiga | $19 | $140,551113 claims |
| PfizerEliquis | $38 | $95,08465 claims |
| Johnson & JohnsonXarelto | $55 | $24,96017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Naveen BellamOrlando$414K
- Stacy MandrasOrlando$100K
- Pujan PatelOrlando$66K
- Andrija VidicOrlando$18K
- Shahid QamarOrlando$9K
- Jacqueline DoweOrlando$7K
- Sushma KoneruOrlando$7K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.